Bonus Biogroup (BONS) - Net Assets

Latest as of December 2025: ILA-5.66 Million ILA ≈ $-15.18K USD

Based on the latest financial reports, Bonus Biogroup (BONS) has net assets worth ILA-5.66 Million ILA (≈ $-15.18K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA15.44 Million ≈ $41.40K USD) and total liabilities (ILA21.11 Million ≈ $56.58K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of Bonus Biogroup for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	ILA-5.66 Million
% of Total Assets	-36.68%
Annual Growth Rate	N/A
5-Year Change	-106.71%
10-Year Change	N/A
Growth Volatility	131.26

Bonus Biogroup - Net Assets Trend (2008–2025)

This chart illustrates how Bonus Biogroup's net assets have evolved over time, based on quarterly financial data. Check BONS tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Bonus Biogroup (2008–2025)

The table below shows the annual net assets of Bonus Biogroup from 2008 to 2025. For live valuation and market cap data, see BONS market cap overview.

Year	Net Assets	Change
2025-12-31	ILA-5.66 Million ≈ $-15.18K	-181.41%
2024-12-31	ILA6.96 Million ≈ $18.65K	-76.26%
2023-12-31	ILA29.30 Million ≈ $78.57K	-48.03%
2022-12-31	ILA56.39 Million ≈ $151.18K	-33.21%
2021-12-31	ILA84.43 Million ≈ $226.35K	+175.16%
2020-12-31	ILA30.68 Million ≈ $82.26K	+323.63%
2019-12-31	ILA-13.72 Million ≈ $-36.79K	-331.89%
2018-12-31	ILA-3.18 Million ≈ $-8.52K	+50.23%
2017-12-31	ILA-6.38 Million ≈ $-17.12K	+13.30%
2016-12-31	ILA-7.36 Million ≈ $-19.74K	-430.09%
2015-12-31	ILA-1.39 Million ≈ $-3.72K	-329.97%
2014-12-31	ILA604.00K ≈ $1.62K	-90.63%
2013-12-31	ILA6.45 Million ≈ $17.28K	-13.74%
2012-12-31	ILA7.47 Million ≈ $20.03K	+948.13%
2011-12-31	ILA-881.00K ≈ $-2.36K	+97.69%
2010-12-31	ILA-38.19 Million ≈ $-102.39K	-307.07%
2009-12-31	ILA-9.38 Million ≈ $-25.15K	-179.08%
2008-12-31	ILA11.86 Million ≈ $31.81K	--

Equity Component Analysis

This analysis shows how different components contribute to Bonus Biogroup's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 33982000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	ILA306.47 Million	%
Other Comprehensive Income	ILA49.96 Million	%
Total Equity	ILA-5.66 Million	100.00%

Bonus Biogroup Competitors by Market Cap

The table below lists competitors of Bonus Biogroup ranked by their market capitalization.

Company	Market Cap
Cartica Acquisition Corp NASDAQ:CITE	$86.44 Million
Maywufa Co Ltd TW:1731	$86.47 Million
Applied BioCode TW:6598	$86.48 Million
IBI Lion SOCIMI S.A. MC:YIBI	$86.48 Million
Terracom Ltd AU:TER	$86.40 Million
Torque Metals Ltd AU:TOR	$86.36 Million
Haivision Systems Inc TO:HAI	$86.35 Million
G Collado S.A.B. de C.V MX:COLLADO	$86.35 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Bonus Biogroup's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 6,957,000 to -5,664,000, a change of -12,621,000 (-181.4%).
Net loss of 24,490,000 reduced equity.
New share issuances of 9,905,000 increased equity.
Other comprehensive income increased equity by 8,714,001.
Other factors decreased equity by 6,750,001.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	ILA-24.49 Million	-432.38%
Share Issuances	ILA9.90 Million	+174.88%
Other Comprehensive Income	ILA8.71 Million	+153.85%
Other Changes	ILA-6.75 Million	-119.17%
Total Change	ILA-	-181.41%

Book Value vs Market Value Analysis

This analysis compares Bonus Biogroup's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2012-12-31	ILA0.04	ILA27.60	x
2013-12-31	ILA0.04	ILA27.60	x
2014-12-31	ILA0.00	ILA27.60	x
2015-12-31	ILA-0.01	ILA27.60	x
2016-12-31	ILA-0.03	ILA27.60	x
2017-12-31	ILA-0.01	ILA27.60	x
2018-12-31	ILA0.00	ILA27.60	x
2019-12-31	ILA-0.02	ILA27.60	x
2020-12-31	ILA0.03	ILA27.60	x
2021-12-31	ILA0.15	ILA27.60	x
2022-12-31	ILA0.09	ILA27.60	x
2023-12-31	ILA0.03	ILA27.60	x
2024-12-31	ILA0.01	ILA27.60	x
2025-12-31	ILA-0.01	ILA27.60	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Bonus Biogroup utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-167.67%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2008	1.15%	0.24%	1.10x	4.28x	ILA-1.05 Million
2009	0.00%	-23.22%	1.89x	0.00x	ILA-20.74 Million
2010	0.00%	-22.96%	5.29x	0.00x	ILA-3.55 Million
2011	-28.29%	0.00%	0.00x	0.00x	ILA-1.40 Million
2012	-240.54%	0.00%	0.00x	1.18x	ILA-18.72 Million
2013	-150.52%	0.00%	0.00x	1.27x	ILA-10.35 Million
2014	-1855.46%	0.00%	0.00x	7.49x	ILA-11.27 Million
2015	0.00%	0.00%	0.00x	0.00x	ILA-13.32 Million
2016	0.00%	0.00%	0.00x	0.00x	ILA-15.31 Million
2017	0.00%	0.00%	0.00x	0.00x	ILA-19.56 Million
2018	0.00%	0.00%	0.00x	0.00x	ILA-18.42 Million
2019	0.00%	0.00%	0.00x	0.00x	ILA-20.87 Million
2020	-71.77%	0.00%	0.00x	1.68x	ILA-25.09 Million
2021	-106.69%	0.00%	0.00x	1.24x	ILA-98.52 Million
2022	-68.64%	0.00%	0.00x	1.32x	ILA-44.34 Million
2023	-97.35%	0.00%	0.00x	1.53x	ILA-31.46 Million
2024	-399.97%	0.00%	0.00x	3.36x	ILA-28.52 Million
2025	0.00%	0.00%	0.00x	0.00x	ILA-23.92 Million

Industry Comparison

This section compares Bonus Biogroup's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $83,025,035
Average return on equity (ROE) among peers: -61.41%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Bonus Biogroup (BONS)	ILA-5.66 Million	1.15%	N/A	$86.42 Million
BioLine RX Ltd (BLRX)	$22.53 Million	-58.52%	0.30x	$11.20 Million
BioLight Life Sciences Ltd (BOLT)	$30.30 Million	-85.87%	0.10x	$10.44 Million
Can Fite Biopharma Ltd (CANF)	$13.07 Million	-28.13%	0.42x	$6.08 Million
Clal Biotechnology Industries Ltd (CBI)	$497.85 Million	-30.96%	0.24x	$11.31 Million
Compugen (CGEN)	$92.51 Million	-14.49%	0.06x	$176.69 Million
DNA Biomed Solns (DNA)	$80.11 Million	-29.38%	0.02x	$32.49 Million
Enlivex Therapeutics Ltd (ENLV)	$75.00K	-305.33%	1.08x	$2.98 Million
Evogene (EVGN)	$19.34 Million	0.00%	1.22x	$4.25 Million
Kadimastem Ltd (KDST)	$-8.56 Million	0.00%	0.00x	$22.18 Million

About Bonus Biogroup

TA:BONS Israel Biotechnology

Market Cap

$86.42 Million

ILA32.23 Billion ILA

Market Cap Rank

#19678 Global

#256 in Israel

Share Price

ILA27.60

Change (1 day)

-1.08%

52-Week Range

ILA21.10 - ILA58.50

All Time High

ILA171.00